Proactive Investors - Run By Investors For Investors

Pharmaxis LOXL2 program phase 2 ready after completion of 13-week toxicity studies

The results of the toxicity studies complete Pharmaxis’ scientific package of data for the LOXL2 program.
liver on a human body
Pharmaxis’ LOXL2 inhibitors have the potential to treat fibrotic diseases

Pharmaxis Ltd (ASX:PXS) has now received reports on all of the 13‐week toxicity studies conducted for each of its two Lysyl Oxidase Like 2 (LOXL2) inhibitors.

The company is now ready to enter phase 2 clinical studies for fibrotic diseases such as non‐alcoholic steatohepatitis (NASH), cardiac fibrosis and idiopathic pulmonary fibrosis (IPF).

Adequate safety margin to start phase 2 studies

Both the drug compounds were tested at a range of doses in two species over a 13‐week period to establish the No Observed Adverse Effect Level (NOAEL). 

For both compounds, doses that resulted in 85% or greater inhibition of the target enzyme in the phase 1 studies were below the human equivalent NOAEL doses in all toxicity studies and therefore an adequate safety margin to start phase 2 studies of up to three months in length.  

With the data package complete, Pharmaxis is now conducting a final series of scientific briefings to potential partners.

READ: Pharmaxis resubmits new drug application for Bronchitol in the US

Pharmaxis chief executive officer Gary Phillips said: “The results of the toxicity studies complete our scientific package of data for the LOXL2 program. 

“It is a high quality and comprehensive data package that is a testament to the expertise and experience of the Drug Discovery and Clinical Development teams at Pharmaxis.

READ: Pharmaxis reveals first sales of Aridol® in US following successful relaunch

“We have provided the large pharma companies who have been closely monitoring our progress with the latest study results and are now in the process of supporting them to complete their scientific due diligence. 

“We are keen to answer remaining scientific questions of potential partners, discuss their proposed clinical development strategies should they acquire or license the program and progress discussions concerning appropriate commercial terms.”

 

Pharmaxis’ LOXL2 program compounds are highly selective small molecule inhibitors of LOXL2 that can be administered orally and the completed pre‐clinical development program supports the potential of both compounds to treat fibrotic disease in one or more organs.

View full PXS profile View Profile

Pharmaxis Ltd Timeline

Related Articles

scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
Artificial intelligence
October 29 2018
E-therapeutics believes it is now focused on the right activities
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use